drugset / Trial / NCT00693472

Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)

NCT00693472

Phase 2 Terminated 46 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to evaluate the effectiveness of preladenant in the prevention (Part 1) or treatment (Part 2) of antipsychotic induced akathisia in participants with acute psychosis using the Barnes Akathisia Scale.

Timeline

Start
2007-08-15
Primary completion
2008-12-12
Completion
2009-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Preladenant Small molecule 25 mg Oral
Background Haloperidol Other / unclassified 7.5 mg Oral
Background Propranolol Small molecule